New research found that over half of people with type 2 diabetes in the Americas may be deficient in essential nutrients, ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...

"Yo-yo" dieting --- repeatedly losing and gaining weight -- can significantly increase risk of kidney disease among people ...

Use of a sodium-glucose cotransporter 2, or SGLT2, inhibitor combined with calorie restriction resulted in greater rates of type 2 diabetes remission compared with calorie restriction alone, according ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

A recent study from the University of Hong Kong suggests that a newer type of diabetes drug, called sodium-glucose cotransporter 2 inhibitors (SGLT2i), may help protect the kidneys and lungs in people ...

The study could not account for other mediators of cardiovascular risk and breastfeeding, such as social determinants of ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Dr. Nakita Cropper with Atlantic General Hospital is no stranger to the odds that can be stacked against Black health care ...

Managing low blood sugar can be tough sometimes. Here, RDs share their recommendations for best foods to get things back on ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...